Microbead Monophasic Tech
November 23, 2023
The attainment of the hyaluronic acid gel's viscosity is intricately tied to the crosslinking process, wherein binding agents play a pivotal role in connecting individual HA molecules. Serving as a linking agent in this chemical transformation, the Divinyl Sulfone (DVS) molecule modifies the structure of HA, crafting stable three-dimensional hydrogel networks with manifold applications in the biomedical realm. Notably, it finds utility in soft tissue augmentation through the application of HA gel.
A Molecular Revolution
In contrast to the widely adopted 1,4 Butanediol diglyceryl ether (BDDE), a commonplace crosslinking agent in HA dermal fillers, LifDerma introduces a groundbreaking crosslink with DMCT®️ (Divinyl Sulfone Multi-Crosslink Technology), distinguished by its molecular lightness and brevity. At the molecular level, DVS necessitates approximately three times fewer atoms for the interconnection of HA molecules compared to BDDE.
Despite its diminutive size, DVS exhibits an exceptional capacity to bind with the entirety of HA molecules, achieving a comprehensive crosslinking that surpasses what is attainable with BDDE. This heightened degree of crosslinking translates into diminished post-treatment swelling following HA gel injections, expediting the realization of final results while mitigating potential side effects.
The smaller size and fewer involved atoms render DVS wholly absorbable by the human body, leaving no residual effects. Furthermore, the binding of DVS enhances mechanical stability and fortifies resistance to enzymatic degradation within the HA gel, ensuring enduring and robust outcomes.
With reduced swelling, heightened gel stability, enhanced injection precision, and minimized pendant effects, LifDerma introduces a transformative chapter in the history of Hyaluronic Acid, heralding advancements that promise unparalleled efficacy in the realm of dermal treatments.
Supporting Articles links:
